

IACH 2020 Scientific Program

Meeting co-chairs: Mohamad Mohty, Arnon Nagler, Jordi Sierra

Local co-chairs: Didier Blaise, Thomas Cluzeau

Thursday, October 1, 2020 (all times CET)	
14:30-15:50	Session 1: The 2020 highlights in ...
	<i>Opening remarks:</i> Mohamad Mohty , France & Arnon Nagler , Israel
	... high-risk AML: Arnon Nagler , Israel
	... CML: François Guilhot , France
	... MDS: Thomas Cluzeau , France
15:50-17:00	Session 2: Advances in AML biology
	Role of NPM1 mutation: Brunangelo Falini , Italy
	Impact of microbiota modulation: Florent Malard , France
	Panel discussion
17:00-18:15	Session 3: The hard to treat patients
	Relapsed/refractory B-ALL: Dieter Hoelzer , Germany
	Relapsed/refractory T-ALL: Eolia Brissot , France
	Transplant for refractory AML: Mohamad Mohty , France
	Panel discussion
18:15-19:00	Session 4: H.J. Khoury award
	H.J. Khoury award presentation
	PML, an unexpected effector of therapy response in APL and other malignancies: Hugues de Thé , France

Friday, October 2, 2020 (all times CET)	
08:30-10:10	Session 5: Remission and post-remission therapy in high-risk acute leukemia
	Induction therapy in AML: Michael Loschi , France
	Allo-transplant in AML: Jordi Sierra , Spain
	Autologous transplantation in AML: Norbert-Claude Gorin , France
	Allo-transplant in ALL: Sebastian Giebel , Poland
	Panel discussion
10:10-11:40	Your decisions in action: the reality of severe hepatic VOD management <small>This symposium is organised and funded by Jazz Pharmaceuticals for healthcare professionals only</small>
11:40-13:20	Session 6: CAR-T cells in ALL
	Recent results in children: André Baruchel , France
	Recent results in adults: Christian Chabannon , France
	Experience from China: He Huang , China
	Management of toxicities: Bipin Savani , USA
13:20-14:05	Your Questions Answered, with Professor Mohty <small>An opportunity to ask your questions to Professor Mohty on HCT, HCT in the era of COVID and post-transplant complications This meeting is organised and funded by Jazz Pharmaceuticals for healthcare professionals only. This session is hosted on the Jazz Pharmaceuticals exhibition stand.</small>
14:05-16:10	Session 7: Management of elderly leukemia
	AML: Farhad Ravandi , USA
	Transplant for elderly leukemia: Didier Blaise , France
	Supportive care: Bipin Savani , USA
	Transplant for MDS: Ibrahim Yakoub-Agha , France
	Panel discussion
16:10-17:00	Optimising Outcomes with Pre-Transplant Treatment Selection in high-risk AML* <small>*High-risk AML defined as therapy-related AML (t-AML) or AML with myelodysplasia-related changes (AML-MRC) This symposium is organised and funded by Jazz Pharmaceuticals for healthcare professionals only</small>

Saturday, October 3, 2020 (all times CET)	
08:30-9:50	Session 8: Management of rare leukemias
	Plasmacytoid dendritic cell leukemia: Naveen Pemmaraju , USA
	ATL and HTLV-related disorders: Ali Bazarbachi , Lebanon
	Acute promyelocytic leukemia: Miguel Sanz , Spain
9:50-11:20	Session 9: Novel drugs in leukemia
	BTK inhibitors: Gianluca Gaidano , Italy
	Antibody-drug conjugates: Norbert Vey , France
	BCL-2 inhibitors: Thomas Prebet , USA
	Panel discussion
11:20-13:00	Closing lectures
	Advances in ALL therapy: Hagop Kantarjian , USA
	Flt3 inhibitors in AML: Richard Stone , USA
	Novel drugs development, evaluation and access: Jean-Luc Harousseau , France
	Closing remarks